# Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma

> **NCT04486391** · PHASE3 · TERMINATED · sponsor: **BeiGene** · enrollment: 3 (actual)

## Conditions studied

- Classical Hodgkin Lymphoma

## Interventions

- **DRUG:** Tislelizumab
- **DRUG:** Salvage Chemotherapy

## Key facts

- **NCT ID:** NCT04486391
- **Lead sponsor:** BeiGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-12-14
- **Primary completion:** 2025-10-13
- **Final completion:** 2025-10-13
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Study has voluntarily discontinued due to a change in the company-level development strategy and is not because of any safety concern.
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04486391

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04486391, "Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04486391. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*